Affiliation:
1. Department of Pharmacology, Grant Government Medical College and Sir J.J Group of Hospitals, Mumbai, Maharashtra, India,
Abstract
The respiratory tract infection known as coronavirus disease 2019 (COVID-19) was first discovered in Wuhan, China, in December 2019. This disease causes symptoms such as fever, chills, cough and shortness of breath. Hydroxychloroquine (HCQ) was used for treatment as well as prophylaxis of mild cases of COVID-19 (postulated mechanism of viral replication reduction). HCQ has known safety in malaria and autoimmune diseases. However, its safety in COVID-19 is not proven. The patient, in this case, was detected COVID-19 reverse transcription polymerase chain reaction positive and was started with Tab. HCQ, along with home quarantine. On day 2, she developed blurred vision and reading difficulty. After obtaining an ophthalmologist referral, no change was made in the treatment. Once 7 days of Tab. HCQ treatment was over, and the vision resolved spontaneously. Cardiac side effects of HCQ have always been a focus, but ocular manifestations also need to be considered. HCQ-induced vortex keratopathy is generally seen after 2 weeks, but this COVID-19 patient developed it within the first 2 days, which makes this case unusual.